EA201300974A1 - Терапия неврологических заболеваний на основе баклофена и акампросата - Google Patents

Терапия неврологических заболеваний на основе баклофена и акампросата

Info

Publication number
EA201300974A1
EA201300974A1 EA201300974A EA201300974A EA201300974A1 EA 201300974 A1 EA201300974 A1 EA 201300974A1 EA 201300974 A EA201300974 A EA 201300974A EA 201300974 A EA201300974 A EA 201300974A EA 201300974 A1 EA201300974 A1 EA 201300974A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
neurological diseases
therapy
baclophene
acamprosat
Prior art date
Application number
EA201300974A
Other languages
English (en)
Other versions
EA023277B1 (ru
Inventor
Даниель Коэн
Илья Чумаков
Сергей Набирочкин
Эмманюэль Вьяль
Микаэль Гуэдж
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201300974A1 publication Critical patent/EA201300974A1/ru
Publication of EA023277B1 publication Critical patent/EA023277B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается комбинаций и способов лечения неврологических заболеваний, связанных с эксцитотоксичностью глутамата и токсичностью β-амилоида. В частности, настоящее изобретение касается новой комбинированной терапии рассеянного склероза, болезни Альцгеймера и родственных ей заболеваний, бокового амиотрофического склероза, болезни Паркинсона, болезни Хантингтона, невропатических болей, алкогольной нейропатии, алкоголизма или синдрома отмены алкоголя либо травмы спинного мозга на основе комбинации баклофена и акампросата.
EA201300974A 2011-03-01 2012-03-01 Терапия неврологических заболеваний на основе баклофена и акампросата EA023277B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305217 2011-03-01
US201161468658P 2011-03-29 2011-03-29
US201161493606P 2011-06-06 2011-06-06
EP11305687 2011-06-06
PCT/EP2012/053570 WO2012117076A2 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurogical disorders

Publications (2)

Publication Number Publication Date
EA201300974A1 true EA201300974A1 (ru) 2014-01-30
EA023277B1 EA023277B1 (ru) 2016-05-31

Family

ID=46758335

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201300974A EA023277B1 (ru) 2011-03-01 2012-03-01 Терапия неврологических заболеваний на основе баклофена и акампросата
EA201891833A EA201891833A1 (ru) 2011-03-01 2013-02-28 Комбинация для лечения амиотрофического бокового склероза или родственных болезней

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201891833A EA201891833A1 (ru) 2011-03-01 2013-02-28 Комбинация для лечения амиотрофического бокового склероза или родственных болезней

Country Status (27)

Country Link
US (7) US9820978B2 (ru)
EP (5) EP2560631B1 (ru)
JP (2) JP5987008B2 (ru)
KR (2) KR101918745B1 (ru)
CN (2) CN105997969B (ru)
AU (2) AU2012222351B2 (ru)
BR (1) BR112013022112B1 (ru)
CA (1) CA2828765C (ru)
CY (3) CY1115074T1 (ru)
DK (3) DK2796132T3 (ru)
EA (2) EA023277B1 (ru)
ES (5) ES2698927T3 (ru)
HK (2) HK1182615A1 (ru)
HR (1) HRP20140131T1 (ru)
HU (1) HUE038653T2 (ru)
IL (2) IL228177B (ru)
LT (2) LT2796132T (ru)
MX (1) MX340568B (ru)
PL (3) PL2560631T3 (ru)
PT (1) PT2560631E (ru)
RS (3) RS53227B (ru)
SG (2) SG192968A1 (ru)
SI (3) SI2796132T1 (ru)
SM (1) SMT201400029B (ru)
TR (1) TR201809351T4 (ru)
WO (2) WO2012117076A2 (ru)
ZA (1) ZA201306039B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2560631B1 (en) 2011-03-01 2014-01-15 Pharnext Baclofen and acamprosate based therapy of neurogical disorders
CN104487064B (zh) * 2012-03-01 2018-01-26 法耐斯特公司 用于治疗肌萎缩性侧索硬化症的新组合物
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
GB2565939A (en) 2012-02-10 2019-02-27 Rational Intellectual Holdings Ltd Method and system for operating instances of a game
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
EP3235498A1 (en) * 2012-03-01 2017-10-25 Pharnext New compositions for treating amyotrophic lateral sclerosis
WO2014013025A1 (en) * 2012-07-18 2014-01-23 Pharnext Baclofen and acamprosate based therapy of macular degeneration disorders
EP2705841A1 (en) 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
NZ714684A (en) 2013-06-05 2020-05-29 Pharnext Stable oral solutions for combined api
CA2915811C (en) * 2013-06-19 2021-08-31 Som Innovation Biotech, S.L. Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
KR102206745B1 (ko) * 2013-07-12 2021-02-03 경상대학교산학협력단 안토시아닌 및 gabab 수용체 작용제를 유효성분으로 포함하는 신경질환 치료제
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
EP3062782A1 (en) * 2013-10-30 2016-09-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
BR112017010423B1 (pt) * 2014-11-21 2023-09-26 Biohaven Pharmaceutical Holding Company Ltd. Formulação sublingual de riluzol e uso da mesma
KR20170142180A (ko) 2015-05-04 2017-12-27 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
WO2017115873A1 (ja) 2015-12-29 2017-07-06 国立大学法人京都大学 アルツハイマー病の予防及び／又は治療剤
AU2017216288B2 (en) * 2016-02-05 2022-06-02 Pharnext Novel combinatorial therapies of neurological disorders
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
JP7065880B2 (ja) * 2017-04-24 2022-05-12 ファーネクスト アルツハイマー病のイダロピルジン系組合せ療法
US20200163895A1 (en) * 2017-05-17 2020-05-28 Confluence Pharmaceuticals, Llc Formulations of homotaurines and salts thereof
US11878001B2 (en) 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
WO2019145523A1 (en) * 2018-01-29 2019-08-01 Pharnext Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en) 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
WO2001058476A2 (en) 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
AP2004002951A0 (en) 2001-07-19 2004-03-31 Pharmacia Corp "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
JP2005522466A (ja) 2002-03-18 2005-07-28 ファルマシア・コーポレーション アルドステロン受容体アンタゴニスト、およびニコチン酸またはニコチン酸誘導体の組合わせ
US20040102525A1 (en) 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CN102702065A (zh) 2003-12-30 2012-10-03 什诺波特有限公司 酰氧基烃基氨基甲酸酯前药及其中间体的合成
CA2588868A1 (en) 2004-11-30 2006-06-08 Osaka University Remedy for alzheimer's disease
US20080188510A1 (en) 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2655029A1 (en) 2006-07-06 2008-01-10 Roskamp Research, Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
WO2008086492A1 (en) 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
PL2157973T3 (pl) 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
US20090069419A1 (en) 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009052191A1 (en) 2007-10-15 2009-04-23 Xenoport, Inc. Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009061934A1 (en) 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
SI2282778T1 (sl) * 2008-04-29 2017-07-31 Pharnext Novi terapevtski pristopi za zdravljenje Alzheimerjeve bolezni in sorodnih motenj z modulacijo angiogenezo
CN102065858B (zh) * 2008-04-29 2014-07-02 法奈科斯公司 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
CN102065897B (zh) * 2008-04-29 2013-11-13 法奈科斯公司 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
RU2489433C9 (ru) 2008-11-27 2014-06-10 Нэшнл Юниверсити Корпорейшн Кагава Юниверсити Производное циклобутилпурина, агент, активирующий ангиогенез, агент, активирующий образование просвета, агент, активирующий рост нейронов, и лекарственное средство
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2010102071A1 (en) 2009-03-03 2010-09-10 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
US8344028B2 (en) 2009-04-17 2013-01-01 Xenoport, Inc. Gamma-amino-butyric acid derivatives as GABAB receptor ligands
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
EP2560631B1 (en) 2011-03-01 2014-01-15 Pharnext Baclofen and acamprosate based therapy of neurogical disorders
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders

Also Published As

Publication number Publication date
US20130090307A1 (en) 2013-04-11
WO2012117076A2 (en) 2012-09-07
EP2727588A1 (en) 2014-05-07
JP2017193562A (ja) 2017-10-26
DK2727588T3 (en) 2018-12-10
HK1182615A1 (en) 2013-12-06
SG10201610587SA (en) 2017-02-27
MX340568B (es) 2016-07-14
SI2560631T1 (sl) 2014-06-30
JP6416328B2 (ja) 2018-10-31
BR112013022112B1 (pt) 2021-09-28
AU2017210501B2 (en) 2018-11-01
DK2560631T3 (da) 2014-02-10
WO2012117075A3 (en) 2012-12-13
HK1203158A1 (en) 2015-10-23
AU2012222351B2 (en) 2017-05-18
CY1120925T1 (el) 2019-12-11
US20140378440A1 (en) 2014-12-25
MX2013010043A (es) 2014-02-11
EP2680835B1 (en) 2018-02-07
EP2680835A2 (en) 2014-01-08
NZ614184A (en) 2015-08-28
CY1115074T1 (el) 2016-12-14
SMT201400029B (it) 2014-07-07
RS58114B1 (sr) 2019-02-28
US20200085790A1 (en) 2020-03-19
HUE038653T2 (hu) 2018-11-28
EP2796132B1 (en) 2018-05-02
HRP20140131T1 (hr) 2014-05-09
CN105997969A (zh) 2016-10-12
JP5987008B2 (ja) 2016-09-06
KR20180043844A (ko) 2018-04-30
US9144558B2 (en) 2015-09-29
US20160000736A1 (en) 2016-01-07
PL2796132T3 (pl) 2018-10-31
LT2727588T (lt) 2019-01-25
SG192968A1 (en) 2013-09-30
WO2012117075A2 (en) 2012-09-07
US9636316B2 (en) 2017-05-02
PT2560631E (pt) 2014-02-24
PL2560631T3 (pl) 2014-06-30
EP3332781A1 (en) 2018-06-13
SI2796132T1 (sl) 2018-09-28
ES2665569T3 (es) 2018-04-26
KR101918745B1 (ko) 2018-11-15
KR20140038378A (ko) 2014-03-28
IL261725A (en) 2018-10-31
US8741886B2 (en) 2014-06-03
EP2796132A1 (en) 2014-10-29
WO2012117076A3 (en) 2012-10-26
KR101937782B1 (ko) 2019-01-11
ES2450074T3 (es) 2014-03-21
IL228177B (en) 2018-01-31
EA201891833A1 (ru) 2019-01-31
RS53227B (en) 2014-08-29
JP2014510069A (ja) 2014-04-24
EP2727588B1 (en) 2018-08-29
ES2845204T3 (es) 2021-07-26
US20130085122A1 (en) 2013-04-04
CN103596562B (zh) 2016-06-01
CA2828765A1 (en) 2012-09-07
LT2796132T (lt) 2018-10-10
EP2560631A2 (en) 2013-02-27
AU2017210501A1 (en) 2017-08-17
RS57426B1 (sr) 2018-09-28
AU2012222351A1 (en) 2013-08-29
US9820978B2 (en) 2017-11-21
US20140080873A1 (en) 2014-03-20
CN105997969B (zh) 2022-03-25
CY1120369T1 (el) 2019-07-10
US20170231958A1 (en) 2017-08-17
EP2560631B1 (en) 2014-01-15
CN103596562A (zh) 2014-02-19
CA2828765C (en) 2019-07-30
TR201809351T4 (tr) 2018-07-23
DK2796132T3 (en) 2018-07-23
SI2727588T1 (sl) 2019-03-29
US8865769B2 (en) 2014-10-21
ZA201306039B (en) 2014-10-29
ES2678794T3 (es) 2018-08-17
ES2698927T3 (es) 2019-02-06
PL2727588T3 (pl) 2019-04-30
EA023277B1 (ru) 2016-05-31
BR112013022112A2 (pt) 2018-06-26

Similar Documents

Publication Publication Date Title
EA201300974A1 (ru) Терапия неврологических заболеваний на основе баклофена и акампросата
EA201300975A1 (ru) Новые композиции для лечения неврологических заболеваний
EA201690501A1 (ru) Новые композиции для лечения неврологических расстройств
HK1258231A1 (zh) 治療阿爾茨海默氏症、亨廷頓氏症、孤獨症和其他障礙的方法
WO2014096425A3 (en) Prodrugs of monomethyl fumarate (mmf)
WO2012079072A3 (en) Subcutaneously infusible levodopa prodrug compositions and methods of infusion
BR112015022197A2 (pt) tratamento de cataplexia
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201691602A1 (ru) Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
WO2011107812A3 (en) Stabilized pharmaceutical composition
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
WO2008057609A8 (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
WO2016059269A8 (es) Compuestos derivados de acrilato de 3-alouilamino-1h- indolilo y su uso en el tratamiento de enfermedades neurodegenerativas
MX2015007862A (es) Derivado de amida del acido cinamico.
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
WO2013033602A3 (en) Fatty acid amides, compositions and methods of use
AU2018253542A1 (en) Reducing inter-patient variability of levodopa plasma concentrations
WO2012121862A3 (en) Valproic acid derivative compounds
EA201792076A1 (ru) Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний
SG195233A1 (en) Scyllo-inositol for the treatment of behavioral and psychiatric disorders
TH46474S1 (th) เข็มทางการแพทย์
TH131836S (th) เข็มทางการแพทย์